Stockreport

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with D...

MannKind Corporation  (MNKD) 
Last mannkind corporation earnings: 2/25 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.mannkindcorp.com/press-releases
PDF If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA submission based on data from the Phase 3 INHAL [Read more]